Comment on "An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use"

Ment Health Clin. 2023 Jun 28;13(3):165-166. doi: 10.9740/mhc.2023.06.165. eCollection 2023 Jun.
No abstract available

Grants and funding

Disclosures: This study was sponsored by Alkermes Inc. Medical writing and editorial support were provided by Kathleen Dorries, PhD, and John H. Simmons, MD, of Peloton Advantage LLC, an OPEN Health company, and funded by Alkermes Inc.